L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.

CONCLUSION: L1CAM is an independent predictor of poor survival in endometrial cancer patients undergoing full lymphadenectomy and adjuvant chemotherapy, thus indicating that L1CAM can be clinically used as a biomarker to identify those patients at increased risk of recurrence.
PMID: 31792716 [PubMed - as supplied by publisher]

Source: Ann Oncol - December 1, 2019 Category: Cancer & Oncology Authors: Asano H, Hatanaka KC, Matsuoka R, Dong P, Mitamura T, Konno Y, Kato T, Kobayashi N, Ihira K, Nozaki A, Oku A, Matsuno Y, Hatanaka Y, Watari H Tags: Ann Surg Oncol Source Type: research